

GLAXOSMITHKLINE PLC
Form 6-K
July 28, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 28 July 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc (the 'Company')
Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Sir Andrew Witty
b) Position/status CEO
c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Sale of Ordinary Shares on 27 July 2016 at a price of £16.9350.

- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £16.9350 | 10,000 |
| n/a (single transaction) | |

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2016-07-27
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D S Redfern
b) Position/status Chief Strategy Officer
c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted
 Ordinary shares of 25 pence
 each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction
 The exercise of options over
 26,800 Ordinary Shares,
 granted on 20 February 2007
 under the GlaxoSmithKline
 Share Option Plan.

c) Price(s) and
 volume(s)

Price(s)	Volume(s)
£14.88	26,800
n/a (single transaction)	

d) Aggregated information
 Aggregated volume Price

e) Date of the transaction 2016-07-27

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern

b) Position/status Chief Strategy Officer

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction
 The sale of 26,800 Ordinary
 Shares following the
 exercise of options granted
 on 20 February 2007 under
 the GlaxoSmithKline Share
 Option Plan.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.942	26,800
	n/a (single transaction)	

Aggregated information
d) Aggregated volume Price

e) Date of the transaction	2016-07-27
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

	Ordinary shares of 25 pence each ('Ordinary Shares')
a) Description of the financial instrument	ISIN: GB0009252882

b) Nature of the transaction	The exercise of options over 24,186 Ordinary Shares, granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan.
------------------------------	---

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£11.47	24,186
	n/a (single transaction)	

Aggregated information
d) Aggregated volume Price

e) Date of the transaction	2016-07-27
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D S Redfern
 b) Position/status Chief Strategy Officer
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument ISIN: GB0009252882
 Ordinary shares of 25 pence each ('Ordinary Shares')

- b) Nature of the transaction The sale of 24,186 Ordinary Shares following the exercise of options granted on granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan.

- c) Price(s) and volume(s) Price(s) Volume(s)
 £16.938 24,186
 Aggregated information n/a (single transaction)

- d) Aggregated volume Price

- e) Date of the transaction 2016-07-27
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D S Redfern
 b) Position/status Chief Strategy Officer
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3.

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882						
b) Nature of the transaction	The exercise of options over 2,614 Ordinary Shares, granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan.						
c) Price(s) and volume(s)	<table> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£11.47</td> <td>2,614</td> </tr> <tr> <td colspan="2">n/a (single transaction)</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£11.47	2,614	n/a (single transaction)	
Price(s)	Volume(s)						
£11.47	2,614						
n/a (single transaction)							
d) Aggregated information							
e) Date of the transaction	2016-07-28						
f) Place of the transaction	n/a						

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882				
b) Nature of the transaction	The sale of 2,614 Ordinary Shares following the exercise of options granted on granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan.				
c) Price(s) and volume(s)	<table> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£17.035</td> <td>2,614</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£17.035	2,614
Price(s)	Volume(s)				
£17.035	2,614				

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Aggregated information	n/a (single transaction)
d) Aggregated volume Price	
e) Date of the transaction	2016-07-28
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	Senior Vice President, Human Resources
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	Sale of Ordinary Shares on 28 July 2016 at a price of £16.9757.
------------------------------	---

c) Price(s) and volume(s)	Price(s) Volume(s) £16.9757 43,000 n/a (single transaction)
---------------------------	---

Aggregated information	
d) Aggregated volume Price	

e) Date of the transaction	2016-07-28
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: July 28, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc